Sumary of Nigeria: Nigerian Doctor, Onyema Ogbuagbu in Covid-19 Vaccine Breakthrough:
- An Associate Professor of Medicine and infectious disease specialist at Yale School of Medicine, Ogbuagbu, in an interview with ABC News, said he was super excited by the results, because having a very effective vaccine would help in achieving the so-called herd immunity..
- A 2003 graduate of medicine from the University of Calabar, he noted that currently, there were insufficient doses of the vaccine for everyone at the moment, but contended that enough doses should be available by the first quarter of 2021..
- Ogbuagbu is in the clinician-educator track and Director of the HIV Clinical Trials programme of the Yale AIDS Programme, Section of Infectious Diseases of the Yale School of Medicine..
- His profile obtained from the website of Yale School of Medicine revealed that in response to the COVID pandemic, he was the Yale principal investigator on multiple investigational therapeutic and preventative clinical trials for COVID-19, including remdesivir (now FDA approved), leronlimab and remdesivir and tocilizumab combination therapy as well as the Pfizer/BioNTech Vaccine trial..
- Chibuzo Ogbuagbu (former VC of ABSU and Abia SSG), whose parents had in New Haven CT, when they went for their doctoral programmes at Yale..
- The Ogbuagbus were reported to have returned to Nigeria, where Onyeama studied medicine and then returned to Yale..
- Ogbuagbu’s responsibilities at Yale include educating and training medical students, residents and infectious diseases fellows in various capacities in inpatient and outpatient settings;.
- As a faculty of the HIV training track of the Yale-Internal Medicine primary care programme and for over six years as a faculty of the Human Resources for Health program in Rwanda, he has extensive experience with curriculum development, structuring of residency training programmes, and mentoring residents and faculty..
- In Rwanda, specifically, he mentored medical residents and junior faculty in quality improvement and clinical research projects that were locally relevant and addressing important infectious diseases-related problems (particularly HIV/AIDS and antimicrobial resistance)….